Holen Sie sich die Stockscreener-App
4.32
8.27%
0.33
Handel nachbörslich:
4.38
0.06
+1.39%
Schlusskurs vom Vortag:
$3.99
Offen:
$4.17
24-Stunden-Volumen:
497.84K
Relative Volume:
2.45
Marktkapitalisierung:
$203.61M
Einnahmen:
$7.69M
Nettoeinkommen (Verlust:
$-17.65M
KGV:
-11.54
EPS:
-0.3743
Netto-Cashflow:
$-15.72M
1W Leistung:
+13.98%
1M Leistung:
+52.11%
6M Leistung:
+117.09%
1J Leistung:
+173.31%
1-Tages-Spanne:
$3.90
$4.40
1-Wochen-Bereich:
$3.56
$4.72
52-Wochen-Spanne:
$1.30
$4.72
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
4.32 | 188.05M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Guggenheim | Buy |
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Eingeleitet | China Renaissance | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price - marketbeat.com
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com South Africa
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Sahm
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Sahm
[424B5] Adagene Inc. Prospectus Supplement (Debt Securities) - stocktitan.net
Leerink raises Adagene stock price target to $8 on combination data By Investing.com - Investing.com South Africa
Leerink raises Adagene stock price target to $8 on combination data - Investing.com India
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - wahanariau.com
Adagene sets $3.75 per ADS price for $70M offering - MSN
Adagene prices $70 million public offering at $3.75 per ADS By Investing.com - Investing.com India
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer - TipRanks
Adagene prices $70 million public offering at $3.75 per ADS - Investing.com
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline - TipRanks
Adagene reports 31% response rate in colorectal cancer trial By Investing.com - Investing.com India
Adagene reports 31% response rate in colorectal cancer trial - investing.com
Adagene (Nasdaq: ADAG) prices $70M ADS sale at 30-day VWAP - stocktitan.net
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Bitget
New and existing investors back Adagene’s $70M ADS sale - stocktitan.net
Adagene (ADAG) launches ADS offering to fund ADG126 and pipeline - Stock Titan
Adagene and Incyte target hard-to-treat colorectal cancer - stocktitan.net
Updated Data from Phase 1b/2 Study of Muzastotug in - GlobeNewswire
Adagene (ADAG) reports stronger 20 mg/kg muzastotug results and Fast Track status - stocktitan.net
Why Is ADAG Stock Tanking Today? - Stocktwits
Adagene (NASDAQ:ADAG) Announces Earnings Results, Beats Expectations By $0.24 EPS - marketbeat.com
Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028 - TipRanks
Adagene (NASDAQ: ADAG) revenue jumps in 2025 as losses narrow and cash runway extends - stocktitan.net
Regulatory pressure around China puts Adagene (ADAG) Nasdaq listing at risk - Stock Titan
Cancer drug candidate shows 29% response rate as Adagene funds run to 2028 - stocktitan.net
Empowering Investor Success - Morningstar
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 44.6% - marketbeat.com
ETFs Investing in Adagene, Inc. Sponsored ADR Stocks - tradingview.com
ADAG Stock Price, Quote & Chart | ADAGENE INC-ADR (NASDAQ:ADAG) - ChartMill
AirBoss of America (OTCMKTS:ABSSF) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
Alibaba Group (NYSE:BABA) Stock Price Down 2% on Analyst Downgrade - Defense World
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
North West (TSE:NWC) Stock Crosses Above 200-Day Moving Average – Here’s Why - Defense World
Adagene (NASDAQ:ADAG) Raised to Hold at Wall Street Zen - MarketBeat
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - wahanariau.com
Adagene Inc. (NASDAQ: ADAG) insider reports 2.39M shares, 5.1% stake - Stock Titan
Adagene (NASDAQ: ADAG) CSO reports options and warrant stakes - Stock Titan
Adagene (ADAG) CFO Tam Man Kin details shares, RSUs and options - Stock Titan
Adagene Inc. (ADAG) CEO Peter Luo reports options, RSUs and shares in Form 3 - Stock Titan
Adagene (ADAG) HR executive Form 3 details options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details stock option holdings - Stock Titan
Adagene (ADAG) finance leader lists options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details 70,000-share option position in Form 3 - Stock Titan
Adagene (NASDAQ: ADAG) CMO discloses stock options, RSUs and shares - Stock Titan
Adagene Inc. (ADAG) director lists time and performance stock options - Stock Titan
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - Bitget
Experimental cancer antibody muzastotug in colon and liver trials at AACR 2026 - Stock Titan
Adagene Inc. (ADAG) director discloses 25,000 shares and 65,000 options - Stock Titan
Finanzdaten der Adagene Inc Adr-Aktie (ADAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):